ETF Holdings Breakdown of SNY

SNY institutional holdings

The following institutional investment holdings of SNY have been identified

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share	Comment
2025-11-11	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	174,219	USD 9,005,380	51.69
2025-11-11	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	174,219	USD 9,005,380 2.0%	51.69
Total =		348,438	USD 18,010,760

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with SNY

Sanofi (NASDAQ:SNY) Shares Acquired Rep. Lisa C. McClain

Representative Lisa C. McClain (R-Michigan) recently bought shares of Sanofi (NASDAQ:SNY). In a filing disclosed on September 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Sanofi stock on August 4th. The trade occurred in the Representative’s “CHARLES SCHWAB BROKERAGE ACCOUNT 924” account. Representative Lisa C. McClain also recently made the […] - 2025-09-17 03:08:42

Sanofi's Brivekimig Shows Efficacy In Biologic-Naïve HS Patients In Phase 2a Study

(RTTNews) - Sanofi (SNY) announced promising new data from its HS-OBTAIN phase 2a study, highlighting the efficacy of brivekimig in treating biologic-naïve patients with moderate-to-severe hidradenitis suppurativa (HS). - 2025-09-17 02:33:17

Morgan Stanley Upgrades Sanofi (NASDAQ:SNY) to “Overweight”

Sanofi (NASDAQ:SNY – Get Free Report) was upgraded by Morgan Stanley from an “equal weight” rating to an “overweight” rating in a research note issued on Monday, Marketbeat.com reports. The firm currently has a $58.00 target price on the stock, up from their previous target price of $56.00. Morgan Stanley’s target price suggests a potential […] - 2025-09-10 03:00:55

Sanofi's Amlitelimab Meets Primary & Key Secondary Endpoints In Phase 3 Study For Atopic Dermatitis

(RTTNews) - Sanofi SA's (SAN.PA, SNYNF, SNY) investigational therapy, amlitelimab, has achieved a significant milestone in the COAST 1 phase 3 clinical trial, meeting all primary and key secondary endpoints in adults and adolescents with moderate-to-severe atopic dermatitis. Admi - 2025-09-04 02:27:43

Mitsubishi UFJ Asset Management Co. Ltd. Acquires 253 Shares of Sanofi (NASDAQ:SNY)

Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in Sanofi (NASDAQ:SNY – Free Report) by 6.7% in the 1st quarter, HoldingsChannel reports. The firm owned 4,032 shares of the company’s stock after buying an additional 253 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Sanofi were worth $224,000 as of […] - 2025-08-15 04:47:04

Atria Wealth Solutions Inc. Sells 1,794 Shares of Sanofi (NASDAQ:SNY)

Atria Wealth Solutions Inc. decreased its position in shares of Sanofi (NASDAQ:SNY – Free Report) by 10.2% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 15,855 shares of the company’s stock after selling 1,794 shares during the quarter. Atria Wealth Solutions Inc.’s holdings […] - 2025-08-12 05:09:02

Sanofi (NASDAQ:SNY) Rating Increased to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Sanofi (NASDAQ:SNY – Free Report) from a hold rating to a buy rating in a report published on Saturday morning. Other research analysts have also issued reports about the company. Morgan Stanley set a $56.00 target price on Sanofi in a research report on Monday, June 2nd. Barclays reaffirmed […] - 2025-08-05 02:56:56

Analyzing Sanofi (NASDAQ:SNY) and Roche (OTCMKTS:RHHBY)

Sanofi (NASDAQ:SNY – Get Free Report) and Roche (OTCMKTS:RHHBY – Get Free Report) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, valuation, analyst recommendations and institutional ownership. Valuation & Earnings This table compares Sanofi and Roche”s […] - 2025-08-04 04:30:52

Sanofi (NASDAQ:SNY) versus Roche (OTCMKTS:RHHBY) Critical Comparison

Sanofi (NASDAQ:SNY – Get Free Report) and Roche (OTCMKTS:RHHBY – Get Free Report) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, analyst recommendations and institutional ownership. Insider and Institutional Ownership 14.0% of Sanofi shares are […] - 2025-07-30 03:02:41

Sanofi (NASDAQ:SNY) Shares Sold by Choreo LLC

Choreo LLC lowered its position in shares of Sanofi (NASDAQ:SNY – Free Report) by 21.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 45,889 shares of the company’s stock after selling 12,555 shares during the period. Choreo LLC’s holdings in Sanofi were worth […] - 2025-07-24 08:28:55

Sanofi's SAR446597 Granted FDA Fast Track For Gene Therapy Tackling Vision Loss In AMD

(RTTNews) - Sanofi S.A. (SNYNF,SNY) said that the U.S. Food and Drug Administration has granted fast track designation to SAR446597, a one-time intravitreal gene therapy for the treatment of geographic atrophy (GA) due to age-related macular degeneration or AMD. - 2025-07-16 02:29:02

Cerity Partners LLC Has $10.91 Million Holdings in Sanofi (NASDAQ:SNY)

Cerity Partners LLC increased its stake in shares of Sanofi (NASDAQ:SNY – Free Report) by 62.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 196,726 shares of the company’s stock after buying an additional 75,698 shares during the quarter. Cerity Partners LLC’s […] - 2025-07-15 08:30:17

Concurrent Investment Advisors LLC Decreases Stock Holdings in Sanofi (NASDAQ:SNY)

Concurrent Investment Advisors LLC trimmed its position in shares of Sanofi (NASDAQ:SNY – Free Report) by 74.4% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 9,700 shares of the company’s stock after selling 28,246 shares during the quarter. Concurrent Investment Advisors LLC’s holdings in […] - 2025-07-11 05:50:49

Bank of New York Mellon Corp Sells 840,093 Shares of Sanofi (NASDAQ:SNY)

Bank of New York Mellon Corp lowered its position in Sanofi (NASDAQ:SNY – Free Report) by 30.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,945,223 shares of the company’s stock after selling 840,093 shares during the quarter. Bank of New York […] - 2025-07-10 05:35:08

Leerink Partnrs Estimates Sanofi’s Q2 Earnings (NASDAQ:SNY)

Sanofi (NASDAQ:SNY – Free Report) – Stock analysts at Leerink Partnrs cut their Q2 2025 earnings per share (EPS) estimates for Sanofi in a research report issued to clients and investors on Monday, July 7th. Leerink Partnrs analyst D. Risinger now expects that the company will post earnings per share of $0.94 for the quarter, […] - 2025-07-10 02:17:01

Financial Review: Sanofi (NASDAQ:SNY) & Merck & Co., Inc. (NYSE:MRK)

Sanofi (NASDAQ:SNY – Get Free Report) and Merck & Co., Inc. (NYSE:MRK – Get Free Report) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings and dividends. Insider and Institutional Ownership 14.0% of […] - 2025-07-09 05:36:55

Leerink Partnrs Predicts Sanofi’s Q3 Earnings (NASDAQ:SNY)

Sanofi (NASDAQ:SNY – Free Report) – Research analysts at Leerink Partnrs raised their Q3 2025 EPS estimates for Sanofi in a report issued on Monday, July 7th. Leerink Partnrs analyst D. Risinger now forecasts that the company will post earnings of $1.77 per share for the quarter, up from their previous estimate of $1.76. The […] - 2025-07-09 02:10:51

Private Trust Co. NA Purchases 697 Shares of Sanofi (NASDAQ:SNY)

Private Trust Co. NA raised its position in Sanofi (NASDAQ:SNY – Free Report) by 19.8% in the 1st quarter, Holdings Channel reports. The firm owned 4,220 shares of the company’s stock after buying an additional 697 shares during the quarter. Private Trust Co. NA’s holdings in Sanofi were worth $234,000 at the end of the […] - 2025-07-08 04:52:56

Analysts Set Sanofi (NASDAQ:SNY) Price Target at $61.50

Sanofi (NASDAQ:SNY – Get Free Report) has been assigned an average rating of “Buy” from the eight ratings firms that are currently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, three have given a buy rating and three have assigned a strong buy rating to […] - 2025-07-02 02:22:53

Sanofi (NASDAQ:SNY) Shares Sold by Transcend Capital Advisors LLC

Transcend Capital Advisors LLC lowered its stake in shares of Sanofi (NASDAQ:SNY – Free Report) by 30.7% in the first quarter, HoldingsChannel reports. The fund owned 3,895 shares of the company’s stock after selling 1,728 shares during the quarter. Transcend Capital Advisors LLC’s holdings in Sanofi were worth $216,000 at the end of the most […] - 2025-07-01 05:26:59

Sequoia Financial Advisors LLC Increases Stake in Sanofi (NASDAQ:SNY)

Sequoia Financial Advisors LLC increased its position in shares of Sanofi (NASDAQ:SNY – Free Report) by 15.6% during the 1st quarter, Holdings Channel reports. The institutional investor owned 24,272 shares of the company’s stock after purchasing an additional 3,269 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Sanofi were worth $1,346,000 at the […] - 2025-06-30 05:37:03

Sanofi's Sarclisa Recommended For EU Approval To Treat Transplant-eligible Newly Diagnosed MM

(RTTNews) - French drug major Sanofi S.A. (SNYNF,SNY) announced Monday that Sarclisa (isatuximab) has been recommended for European Union approval by the Committee for Medicinal Products for Human Use or CHMP to treat transplant-eligible newly diagnosed multiple myeloma, based on - 2025-06-23 02:53:56

Sanofi (NASDAQ:SNY) Shares Sold by Johnson Investment Counsel Inc.

Johnson Investment Counsel Inc. lowered its position in Sanofi (NASDAQ:SNY – Free Report) by 12.6% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,096 shares of the company’s stock after selling 1,750 shares during the quarter. Johnson Investment Counsel Inc.’s holdings in Sanofi were […] - 2025-06-22 06:54:55

Regeneron, Sanofi: FDA Approves Dupixent To Treat Adult Patients With Bullous Pemphigoid

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and French drug major Sanofi S.A. (SNYNF,SNY) announced Friday that the U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid or BP. - 2025-06-20 02:41:27

Brighton Jones LLC Has $271,000 Stock Position in Sanofi (NASDAQ:SNY)

Brighton Jones LLC reduced its stake in shares of Sanofi (NASDAQ:SNY – Free Report) by 9.8% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 4,888 shares of the company’s stock after selling 532 shares during the period. Brighton Jones LLC’s holdings in Sanofi were worth $271,000 […] - 2025-06-19 05:22:53

Fifth Third Bancorp Purchases 1,011 Shares of Sanofi (NASDAQ:SNY)

Fifth Third Bancorp raised its position in shares of Sanofi (NASDAQ:SNY – Free Report) by 4.0% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 26,455 shares of the company’s stock after acquiring an additional 1,011 shares during the quarter. Fifth Third Bancorp’s […] - 2025-06-16 05:32:52

Wedmont Private Capital Acquires 321 Shares of Sanofi (NASDAQ:SNY)

Wedmont Private Capital grew its holdings in shares of Sanofi (NASDAQ:SNY – Free Report) by 5.9% in the 1st quarter, Holdings Channel.com reports. The fund owned 5,750 shares of the company’s stock after purchasing an additional 321 shares during the period. Wedmont Private Capital’s holdings in Sanofi were worth $296,000 at the end of the […] - 2025-06-12 05:34:57

Hennion & Walsh Asset Management Inc. Cuts Stock Position in Sanofi (NASDAQ:SNY)

Hennion & Walsh Asset Management Inc. lessened its holdings in Sanofi (NASDAQ:SNY – Free Report) by 18.8% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 5,488 shares of the company’s stock after selling 1,272 shares during the period. Hennion & Walsh […] - 2025-06-10 04:58:55

Sanofi's Rilzabrutinib Granted FDA's Orphan Drug Designation To Treat Sickle Cell Disease

(RTTNews) - French drug major Sanofi S.A. (SNYNF,SNY) announced Tuesday that the US Food and Drug Administration has granted orphan drug designation to rilzabrutinib for sickle cell disease. This is the fourth orphan drug designation for rilzabrutinib in rare diseases. - 2025-06-03 02:31:33

Sanofi To Acquire Blueprint Medicines In $9.5 Bln Deal

(RTTNews) - Sanofi (SNYNF, SNY) announced Monday that it has agreed to acquire Blueprint Medicines Corp. (BPMC) in a transaction valued at about $9.5 billion on a fully diluted basis, including potential contingent value right payments. - 2025-06-02 02:29:00

Back to Listing

Disclaimer